Provided by Tiger Trade Technology Pte. Ltd.

3SBIO

15.540
-0.610-3.78%
Volume:35.81M
Turnover:559.08M
Market Cap:39.29B
PE:3.88
High:16.120
Open:16.120
Low:15.480
Close:16.150
52wk High:34.905
52wk Low:14.594
Shares:2.53B
HK Float Shares:2.53B
Volume Ratio:2.41
T/O Rate:1.42%
Dividend:0.26
Dividend Rate:1.69%
EPS(LYR):4.006
ROE:35.88%
ROA:22.68%
PB:1.22
PE(LYR):3.88
PS:1.88

Loading ...

Movement Alert|3SBio Rises 5.95% at Open, ASCO Clinical Data for SSGJ-707 Continues to Drive Momentum

Market Focus
·
Jun 01

Stock Track | 3SBio Soars 5.10% Intraday on Positive Clinical Data Presentation at ASCO Annual Meeting

Stock Track
·
May 29

Movement Alert|3SBio Rises 5.1% in Regular Trading, SSGJ-707 Clinical Data Showcased at ASCO Annual Meeting

Market Focus
·
May 29

Stock Track | 3SBIO Plummets 5.09% Intraday on Subsidiary IPO Expiration and Auditor Change

Stock Track
·
May 28

Movement Alert|3SBio Falls 5.25% in Regular Trading, Subsidiary IPO Expiration and Auditor Change Weigh on Sentiment

Market Focus
·
May 28

3SBIO to Appoint KPMG as New Auditor

Stock News
·
May 26

3SBio proposes KPMG as new auditor, replacing EY after 15 years

Reuters
·
May 26

Stock Track | 3SBIO Plummets 5.56% Intraday as Subsidiary Mandi International's IPO Application Expires

Stock Track
·
May 26

Movement Alert|3SBio Falls 5.51% in Regular Trading, Subsidiary Mandi International IPO Application Expires

Market Focus
·
May 26

Zhongtai Securities Maintains "Buy" on 3SBIO, Citing Unlocked Market Value Potential

Deep News
·
May 17

Zhongtai Securities Reiterates "Buy" Rating on 3SBIO (01530), Citing Early-Stage Pipeline with Multiple Potential First-in-Class Candidates for US-China Dual Submissions

Stock News
·
May 15

3SBIO Maintains "Buy" Rating from China Post Securities as Global Value Accelerates Through Multiple Clinical Trials

Stock News
·
May 12

3SBio Adds 34,000 Shares in April After Option Exercises, Keeps Public Float Above 25%

Bulletin Express
·
May 06

Stock Track | 3SBIO Soars 6.03% Intraday as SSS68 Injection Receives IND Approval for Three Indications

Stock Track
·
Apr 30

3SBIO Shares Surge Over 5% as SSS68 Injection Receives IND Approval for Three Indications in China

Stock News
·
Apr 30

三生制药2025年收入近177亿元,核心产品与全球合作驱动业绩大幅增长

Bulletin Express
·
Apr 29

3SBIO 2025 ESG Report: A-Level Rating, 48.49% Cut in Carbon Intensity and Full Anti-Corruption Coverage

Bulletin Express
·
Apr 29

3SBio Shifts to Full Electronic Distribution of Corporate Communications, Urges Non-Registered Shareholders to Submit Email Details

Bulletin Express
·
Apr 29

3SBio Issues Reminder to Shareholders on Shift to Electronic Corporate Communications

Bulletin Express
·
Apr 29

3SBio publishes 2025 annual report

Reuters
·
Apr 29